Which Are The Toughest Diseases Area To Achieve Clinical Success In?
Executive Summary
In the last decade, on average, only one in 10 Phase I drug development programs conducted in the US have successfully advanced all the way to FDA approval. Meanwhile, despite more than a third of industry's R&D budget being spent on Phase III trials, 42% of programs fail to progress from there, according to a new report from BIO and Informa's Pharma Intelligence.